<DOC>
	<DOCNO>NCT00308438</DOCNO>
	<brief_summary>The purpose study determine whether investigational compound , ALX-0600 , safe effective treat Crohn 's Disease .</brief_summary>
	<brief_title>Safety Efficacy ALX-0600 Subjects With Active Crohn 's Disease Who Completed Protocol CL0600-008</brief_title>
	<detailed_description>The study sixteen week duration twelve week once-daily injection abdomen thigh . There total five visit .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Subjects must complete participation Pilot Active Crohn 's Disease Study . Subjects must continue meet inclusion criterion Pilot Active Crohn 's Disease Study follow exception : CDAI score great 220 Stool sample require Creactive protein level exclusion criterion Subject must continue meet exclusion criterion Pilot Active Crohn 's Disease Study follow exception : Participation clinical study experimental drug device within 30 day sign consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Crohn Disease</keyword>
	<keyword>Crohn 's Disease</keyword>
</DOC>